Photo courtesy Elanco Elanco Animal Health has received full approval from the U.S. Department of Agriculture for its canine parvovirus monoclonal antibody (CPMA) treatment, previously conditionally licensed in 2023. The product, now approved as a therapeutic for canine parvovirus, marks the first USDA-approved treatment for the disease beyond supportive care and will be marketed under the name Trutect. Canine parvovirus is a highly contagious disease that primarily affects puppies and is associated with high mortality rates without treatment. The USDA’s full approval follows earlier conditional licensure granted to address an unmet medical need. The agency has also approved the product for passive immunity to help prevent parvovirus infection in exposed puppies. “Receiving full USDA approval of our lifesaving parvo treatment reinforces our promise to go beyond for veterinarians, pet owners, and, most importantly, the puppies across the country who need it most,” said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation at Elanco. Since its initial availability, Elanco has expanded manufacturing capacity and supported broader access through donations to veterinary clinics and shelters. The company reported that real-world and clinical data submitted to the USDA supported the product’s safety and effectiveness in both treatment and prevention settings. For more information, visit the Elanco website.
